Matryba Paweł, Gawalski Karol, Ciesielska Iga, Horvath Andrea, Bartoszewicz Zbigniew, Sienko Jacek, Ambroziak Urszula, Malesa-Tarasiuk Karolina, Staniszewska Anna, Golab Jakub, Krenke Rafał
Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland.
The Doctoral School of the Medical University of Warsaw, Medical University of Warsaw, 02-097 Warsaw, Poland.
Vaccines (Basel). 2022 Mar 14;10(3):443. doi: 10.3390/vaccines10030443.
An increasing body of evidence from both academic and clinical studies shows that time-of-day exposure to antigens might significantly alter and modulate the development of adaptive immune responses. Considering the immense impact of the COVID-19 pandemic on global health and the diminished efficacy of vaccination in selected populations, such as older and immunocompromised patients, it is critical to search for the most optimal conditions for mounting immune responses against SARS-CoV-2. Hence, we conducted an observational study on 435 healthy young adults vaccinated with two doses of BNT162b2 (Pfizer-BioNTech) vaccine to determine whether time-of-day of vaccination influences either the magnitude of humoral response or number of adverse drug reactions (ADR) being reported. We found no significant differences between morning and afternoon vaccination in terms of both titers of anti-Spike antibodies and frequency of ADR in the studied population. In addition, our analysis of data on the occurrence of ADR in 1324 subjects demonstrated that the second administration of vaccine in those with previous SARS-CoV-2 infection was associated with lower incidence of ADR. In aggregate, vaccination against COVID-19 with two doses of BNT162b2 mRNA vaccine is presumed to generate an equally efficient anti-Spike humoral response.
越来越多的学术研究和临床研究证据表明，一天中不同时间接触抗原可能会显著改变和调节适应性免疫反应的发展。考虑到新冠疫情对全球健康的巨大影响以及在特定人群（如老年人和免疫功能低下患者）中疫苗接种效果的降低，寻找针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）产生免疫反应的最佳条件至关重要。因此，我们对435名接种两剂BNT162b2（辉瑞-生物科技）疫苗的健康年轻成年人进行了一项观察性研究，以确定接种疫苗的时间是否会影响体液反应的强度或所报告的药物不良反应（ADR）的数量。我们发现，在所研究的人群中，上午和下午接种疫苗在抗刺突抗体滴度和ADR频率方面均无显著差异。此外，我们对1324名受试者的ADR发生数据进行的分析表明，既往感染过SARS-CoV-2的人群中第二次接种疫苗与较低的ADR发生率相关。总体而言，接种两剂BNT162b2 mRNA新冠疫苗被认为能产生同样有效的抗刺突体液反应。
